1.1M XNAS Volume
XNAS 22 Apr, 2025 1:11 PM (EDT)
CRISPR Therapeutics AG Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Bearish
Weak Stock
These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
9Positive12Negative
42.9% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
CRISPR Therapeutics AG Stock Price Analysis
Day Price Range | 39.2 (LTP) 38.339.8 LowHigh |
Week Price Range | 39.2 (LTP) 36.739.9 LowHigh |
Month Price Range | 39.2 (LTP) 3042.7 LowHigh |
52 Week Price Range | 39.2 (LTP) 3067.9 LowHigh |
CRISPR Therapeutics AG Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Hit
CRISPR Therapeutics AG's Revenue was higher than average estimate 2 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Miss
EPS is expected to reduce by 12.2% in FY25
Consensus Recommendation
28 ANALYST Recommendations
BUY
The consensus recommendation from 28 analysts for CRISPR Therapeutics AG is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get CRISPR Therapeutics AG Stock Analysis
CRISPR Therapeutics AG stock analysis with key metrics, changes, and trends.
| CRISPR Therapeutics AG Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
|---|---|---|---|---|---|
| Annual Revenue | $35 M | 90.54% | negative |
| |
| Annual Net Profit | $366.25 M | 138.43% | negative |
| |
| Price to Earning Ratio | -9.25 | - | negative |
| |
| Stock Price | $39.24 | -28.72% | negative |
| |
| Quarterly Revenue | $35 M | 82.5% | negative |
| |
| Quarterly Net profit | $37.31 M | 141.76% | negative |
| |
| Debt to Equity Ratio | 0.12 | - | positive |
| |
| Return on Equity(ROE) | -19.20 % | -19.2% | negative |
| |
| Mutual Fund Holding | 67.57 % | -1.55% | negative |
| |
| Promoter Share Holding | 0.50 % | 0.05% | positive |
| |
| Institutional Holding | 77.65 % | 0.01% | positive |
| |
Loading data..
CRISPR Therapeutics AG - Company Profile
What does CRISPR Therapeutics AG do?
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
CRISPR Therapeutics AG Board of directors
All Gross Remunerations are in USD